Table 1. Clinical characteristics of the CLL patients.

Patient	Sex/Age	Stage	Ig Status	CD38/ZAP70a	α4 integrina (%)	β1 integrina (%)
1	M/57	C/IV	ND	−/+	ND	ND
2	M/69	C/IV	ND	−/+	37.0	72.7
3	F/72	C/IV	Mutated	−/+	74.9	99.2
4	M/67	B/II	Mutated	−/+	ND	ND
5	M/65	A/I	Mutated	−/−	78.5	92.0
6	M/79	A/I	Unmutated	−/+	95.1	99.2
7	M/ND	B/III	ND	+/+	82.4	95.0
8	M/79	B/II	Unmutated	+/−	47.3	95.7
9	M/77	A/0	Unmutated	+/ND	45.0	ND
10	F/55	B/II	Unmutated	−/ND	89.0	89.4
11	M/44	B/II	Unmutated	−/+	10.5	63.8
12	M/68	A/0	Mutated	−/+	12.5	41.2
13	M/59	C/IV	Unmutated	+/+	29.9	33.2
14	M/85	C/IV	Unmutated	+/−	25.7	47.1
15	F/73	A/II	Mutated	−/−	75.9	47.8
16	ND	ND	ND	ND	39.8	16.8
17	M/ND	ND	ND	ND	37.0	80.3
18	M/80	B/II	Unmutated	−/+	20.0	37.4
19	F/ND	ND	ND	ND	97.9	17.5
20	M/58	A/II	Mutated	−/ND	50.0	99.0
21	M/48	B/I	Unmutated	+/+	30.0	66.1
22	F/54	B/II	Unmutated	+/−	92.5	82.5
23	ND	ND	ND	ND	ND	ND
24	F/82	C/IV	Unmutated	+/ND	99.2	99.5
25	M/73	B/II	Unmutated	+/+	94.1	98.0
26	F/70	C/IV	ND	+/ND	80.7	78.2
27	M/72	C/IV	Unmutated	+/ND	48.9	54.3
28	M/44	B/II	Unmutated	−/+	18.6	35.0
29	M/61	C/IV	Unmutated	+/ND	60.9	70.9
30	F/69	C/IV	Unmutated	+/ND	99.0	97.4
31	M/79	A/I	ND	−/+	94.0	99.9
32	F/38	C/III	Unmutated	+/+	95.3	91.7
33	F/67	B/II	Unmutated	+/−	97.1	99.3
34	F/55	B/II	Mutated	−/+	98.7	97.0
35	F/65	A/I	Unmutated	−/+	19.8	53.5
36	M/65	B/II	Mutated	−/ND	97.1	92.5
37	M/50	A/0	ND	−/+	40.5	32.5
38	F/69	B/II	ND	−/+	63.2	51.4
39	M/74	B/II	Unmutated	+/+	34.9	51.3
40	M/74	B/II	Mutated	−/ND	26.1	40.9
41	M/73	A/0	ND	−/−	58.3	68.9
42	M/80	A/I	Mutated	−/+	36.2	87.4
43	F/63	A/0	Mutated	−/ND	98.8	95.4
44	M/54	A/0	ND	−/+	95.2	97.0
45	M/ND	ND	Mutated	−/−	45.6	60.0
46	F/45	A/I	Unmutated	−/+	54.3	75.6
47	M/46	A/I	Mutated	−/+	78.4	95.8
48	M/75	B/II	Unmutated	−/+	75.7	73.9

^aThe expression of CD38, ZAP-70 and α4β1 integrin has clinical prognostic value [1, 2]. ND, not determined.